| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-231 | |
| Phytochemical name or plant extracts | Cannabidiolic acid | |
| PMID | 22963825 | |
| Literature evidence | The data presented in this report suggest for the first time that as an active component in the cannabis plant, CBDA offers potential therapeutic modality in the abrogation of cancer cell migration, including aggressive breast cancers. | |
| IUPAC name | 2,4-dihydroxy-3-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-6-pentylbenzoic acid | |
| Phytochemicals’ class or type of plant extracts | Phytocannabinoid | |
| Source of phytochemicals or plant Extracts | Cannabis sativa | |
| Geographical availability | Afghanistan, Kazakhstan, Kirgizstan, Pakistan, Tadzhikistan, Turkmenistan, Uzbekistan, Xinjiang | |
| Plant parts | Leaves | |
| Other cancers | Breast cancer | |
| Target gene or protein | COX-2 | |
| Gene or Protein evidence | Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells. | |
| Target pathways | RhoA signaling pathway | |
| IC50 | NA | |
| Potency | NA | |
| Cell line/ mice model | MDA-MB-231 | |
| Additional information | CBDA inhibits migration of the highly invasive MDA-MB-231 human breast cancer cells, apparently through a mechanism involving inhibition of cAMP-dependent protein kinase A, coupled with an activation of the small GTPase, RhoA. Since cannabis is commonly used in palliative care to treat chemotherapy-associated side effects, further research is required to investigate the potential interference of various cannabis formulations to ensure that the efficacy of chemotherapeutic agents is not compromised. | |
| PubChem ID | 160570 | |
| Additional PMIDs | 25242400 35127309 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:306087-2 | |
| Safety | NA |